Updated WHO recommendations on antenatal corticosteroids and tocolytic therapy for improving preterm birth outcomes
- PMID: 36400080
- PMCID: PMC9681658
- DOI: 10.1016/S2214-109X(22)00434-X
Updated WHO recommendations on antenatal corticosteroids and tocolytic therapy for improving preterm birth outcomes
Conflict of interest statement
We declare no competing interests. The WHO guideline development panel that formulated the antenatal corticosteroids and tocolytics recommendations was an independent, international panel of experts convened by WHO. The panel was co-chaired by GLD and ZPQ. JPV was project manager, and RB and OTO were project coordinators for WHO ACTION-I trial. JPV, RB, and OTO did not take part in the formulation of the recommendations. We would like to acknowledge that this Comment was updated by the Department of Sexual and Reproductive Health and Research and the Department of Maternal, Newborn, Child and Adolescent Health and Ageing at WHO in Geneva. WHO acknowledges the contributions of the many individuals and organisations to the development of these recommendations, including systematic reviewers, members of the Guideline Development Group, and other collaborators.
References
-
- WHO . WHO; Geneva: 2022. WHO recommendation on tocolytics for improving preterm birth outcomes. - PubMed
-
- WHO . WHO; Geneva: 2022. WHO recommendations on antenatal corticosteroids for improving preterm birth outcomes. - PubMed
-
- WHO . World Health Organization; Geneva: 2015. WHO recommendations on interventions to improve preterm birth outcomes. - PubMed
-
- Althabe F, Belizán JM, McClure EM, et al. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial. Lancet. 2015;385:629–639. - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
